Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Terminal uridylyltransferase 1, U6 snRNA-specific (TUT1) is a multifunctional enzyme that acts as both a terminal uridylyltransferase and a non-canonical nuclear poly(A) polymerase. TUT1 localizes to nuclear speckles and is best known for catalyzing the uridylylation of U6 small nuclear RNA (snRNA), a critical RNA species in the spliceosome for mRNA splicing. This enzyme adds oligo-uridines to the 3′ end of newly transcribed U6 snRNA, restoring its characteristic terminal structure and ensuring proper maturation and function in pre-mRNA splicing. Beyond this, TUT1 has context-dependent poly(A) polymerase activity, particularly in the oxidative stress response, where it mediates polyadenylation and 3′ end cleavage of specific mRNAs by facilitating CPSF (cleavage and polyadenylation specificity factor) complex assembly on target RNAs. Structurally, TUT1 contains zinc finger (ZF), RNA recognition motif (RRM), and KA-1 domains along with its catalytic core, allowing multivalent, transient binding to RNA substrates. Its activities help coordinate post-transcriptional gene regulation and have been implicated in cellular stress responses as well as in disease states such as cancer, notably lung cancer where it is upregulated[1][2][3]. No drugs or direct small-molecule inhibitors are currently annotated as interacting with TUT1, and there are no clear biomarkers or safety concerns described in the current literature[3]. TUT1 is a member of terminal nucleotidyltransferases, both as a uridylyltransferase (U6 snRNA-specific) and a regulatory poly(A) polymerase for specific transcripts[2][3]. The enzyme is essential for the correct processing of U6 snRNA and also contributes to alternative polyadenylation of oxidative stress response genes[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Terminal uridylyltransferase 1, U6 snRNA-specific (TUT1).